In adult therapy, arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) are recognized as active treatment of relapsed acute promyelocytic leukemia (APL). The efficacy of this combination in pediatric APL has not yet been well established. We report the case of a 6-year-old girl with relapsed APL, with a PML-RARα mutation, treated with a combination of ATO and ATRA. Over a period of 5 months, she received in total, 75 doses of intravenous ATO and 40 doses of oral ATRA. Currently, 22 months after relapse, she is still in complete remission. Here, we describe treatment of a relapsed APL in a child with limited treatment of ATO and ATRA and review the literature
The outcome of adults and children with Acute Promyelocytic Leukemia (APL) has dramatically changed ...
Acute promyelocytic leukaemia (APL) is a rare subtype ofchildhood acute myeloid leukaemia (AML), acc...
ObjectivesThe efficacy of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) as induction t...
<p>From 2001 to 2013 eleven patients with relapsed acute promyelocytic leukemia (APL) (median age – ...
Since the successful introduction of all-trans-retinoic acid (ATRA) and its combination with anthrac...
The optimal treatment of acute promyelocytic leukaemia (APL) recurring from relapses successfully tr...
Prolonged therapy with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) is highly effective...
Acute promyelocytic leukemia (APL) represents a paradigm of precision medicine. Indeed, in the last ...
Recent studies have demonstrated the beneficial effects of arsenic trioxide (ATO) in the treatment o...
Acute promyelocytic leukemia (APL) is a rare form of acute myeloid leukemia with specific epidemiolo...
To retrospectively analyze the treatment outcomes and side effects of childhood acute promyelocytic ...
Acute promyelocytic leukemia is a variant of acute myeloid leukemia characterized by t(15;17) and PM...
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia characterized by t(15;17) ...
Arsenic trioxide (As2O3) was recently identified as a very potent agent against acute promyelocytic ...
The outcome of adults and children with Acute Promyelocytic Leukemia (APL) has dramatically changed ...
The outcome of adults and children with Acute Promyelocytic Leukemia (APL) has dramatically changed ...
Acute promyelocytic leukaemia (APL) is a rare subtype ofchildhood acute myeloid leukaemia (AML), acc...
ObjectivesThe efficacy of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) as induction t...
<p>From 2001 to 2013 eleven patients with relapsed acute promyelocytic leukemia (APL) (median age – ...
Since the successful introduction of all-trans-retinoic acid (ATRA) and its combination with anthrac...
The optimal treatment of acute promyelocytic leukaemia (APL) recurring from relapses successfully tr...
Prolonged therapy with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) is highly effective...
Acute promyelocytic leukemia (APL) represents a paradigm of precision medicine. Indeed, in the last ...
Recent studies have demonstrated the beneficial effects of arsenic trioxide (ATO) in the treatment o...
Acute promyelocytic leukemia (APL) is a rare form of acute myeloid leukemia with specific epidemiolo...
To retrospectively analyze the treatment outcomes and side effects of childhood acute promyelocytic ...
Acute promyelocytic leukemia is a variant of acute myeloid leukemia characterized by t(15;17) and PM...
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia characterized by t(15;17) ...
Arsenic trioxide (As2O3) was recently identified as a very potent agent against acute promyelocytic ...
The outcome of adults and children with Acute Promyelocytic Leukemia (APL) has dramatically changed ...
The outcome of adults and children with Acute Promyelocytic Leukemia (APL) has dramatically changed ...
Acute promyelocytic leukaemia (APL) is a rare subtype ofchildhood acute myeloid leukaemia (AML), acc...
ObjectivesThe efficacy of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) as induction t...